Related Experiment Video

Updated: Oct 5, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.2K

Adagrasib Moving Ahead in GI Cancers

    Cancer Discovery
    |January 27, 2022
    PubMed

    Insights

    Adagrasib monotherapy achieved a 100% disease control rate in patients with KRASG12C-mutant gastrointestinal tumors, excluding colorectal cancer. These promising early findings are from the KRYSTAL-1 study evaluating this targeted therapy.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Gastroenterology

    Background:

    • The KRASG12C mutation is a key driver in various gastrointestinal cancers, including pancreatic ductal adenocarcinoma.
    • Targeted therapies inhibiting KRASG12C represent a novel treatment strategy for these difficult-to-treat malignancies.

    Discussion:

    • Adagrasib, a selective KRASG12C inhibitor, demonstrated significant efficacy in a Phase II trial.
    • The study focused on patients with KRASG12C-mutant pancreatic ductal adenocarcinoma and other gastrointestinal tumors, excluding colorectal cancer.

    Key Insights:

    • A 100% disease control rate was observed in 27 evaluable patients treated with adagrasib monotherapy.
    • These preliminary results suggest adagrasib's potential as an effective treatment for specific KRASG12C-mutant gastrointestinal cancers.

    Outlook:

    • Further investigation in larger trials is warranted to confirm these findings.
    • Adagrasib may offer a new therapeutic option for patients with limited treatment alternatives.

    More Related Videos

    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

    Published on: September 30, 2016

    13.9K
    Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors03:05

    Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

    Published on: February 16, 2024

    1.2K

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.4K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.9K
    Drugs for Treatment of Diarrhea-Predominant IBS01:17

    Drugs for Treatment of Diarrhea-Predominant IBS

    Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
    Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
    347
    Drugs for Treatment of Ulcerative Colitis in IBD01:29

    Drugs for Treatment of Ulcerative Colitis in IBD

    Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
    257
    Inflammatory Bowel Disease IV: Pharmacological Management01:29

    Inflammatory Bowel Disease IV: Pharmacological Management

    Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
    Pharmacologic...
    222
    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
    282